Saturday, 17th March Eradicate Cancer 2018

Alex Rowland
Probing the Energy Metabolism of Cancer and Immunotherapy

• Modulation of innate immunity for cancer therapy - Bryan Williams
• Targeting cross-presenting dendritic cells with nanoparticulate vaccines for antigen-specific cancer immunotherapy. - Ranjeny Thomas
• Targeting human CD141+ DC for cancer immunotherapy - Kristen Radford
• A preclinical platform for evaluating targeted therapy and immunotherapy combinations in BRAF^V600E melanoma - Emily Lelliott
• Restoring immuno-competency in Chronic Lymphocytic Leukemia - Fabienne Mackay

• Thymic function in T cell reconstitution after cell-ablative therapy - Georg Holländer
• Harnessing natural mechanisms of tissue regeneration to boost immune function in cancer patients - Jarrod Dudakov
• In vitro generation of T cells for therapeutic application - JC Zuniga-Pflucker
• Generation of CTLs from iPSCs transduced with TCR genes: toward the development of “off-the-shelf T cells” - Hiroshi Kawamoto
• Development of functional, mature cytotoxic T-cells from cord HSC via a molecularly-defined, scalable and clinically translatable culture system - Nick Boyd
• The origins of thymic NK cells and ILC1 - Gabrielle Belz

• Multipotential mesenchymal stem/progenitor cells – a novel player in immuno-oncology - Geraldine Storton
• Exploring the interface between ethics and practice: unproven cell therapies in the twilight zone? - John Rasko

Opening by the Honourable John Brumby

Panel:
Joe Trapani, Helen Heslop, Maureen Howard, David Gottlieb, Leigh Dayton, Fabienne MacKay, Rajiv Khanna and   Miles Prince